Tempus AI, Inc.
Tempus AI Inc. (NASDAQ:TEM) shares rose about 11% on Friday, outperforming the Nasdaq and the Healthcare sector, amid an AI-healthcare sector rally. The move followed strong peer results, including Doximity’s fiscal Q1 revenue of $156.6 million, and a strategic collaboration with CellCarta adding Tempus to its CDx lab network. TEM traded near $50.95.
CellCarta (CRO laboratory) said it will add Tempus AI (NASDAQ: TEM) as the second commercial lab partner in its CDx Commercialization Lab Network. Tempus will use Tempus Hub to route oncology companion diagnostic samples to CellCarta and return results to ordering providers. CellCarta also cited Sonic Healthcare USA as the first partner.
Fukushima Ryan (CEO, Data) sold 23,818 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $46.19 ($43.25–$46.94, $1.10M total) across 5 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 4 news stories mentioning TEM (Tempus AI, Inc.). Coverage has skewed bullish: 2 bullish, 2 neutral, and 0 bearish.
Recent TEM coverage spans financial news, market movers and mergers & acquisitions.
In the last 30 days, TEM insiders filed 18 SEC Form 4 transactions — no purchases and 18 sales ($11.6M). The most active reporter was LEFKOFSKY ERIC P, CEO and Chairman, with 12 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Near-term momentum improved on sector strength plus a specific CellCarta collaboration, but longer-term trend remains below key moving averages.
The deal is a commercial distribution and workflow integration win for Tempus in companion diagnostics, but it is not quantified in the release.
This is an insider sale disclosure, not a fundamental update, but it can modestly affect near-term sentiment and positioning.
The article signals a modest consensus target reset for TEM, but it does not provide new fundamentals beyond analyst estimates.
The downgrade in target plus the stock’s proximity to the Personalis termination threshold ($46) increases near-term downside risk and volatility around deal execution.
alphai scores every news story that mentions TEM with an AI model for sentiment and relevance, and aggregates insider trades from Tempus AI, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tempus AI Inc. (NASDAQ:TEM) shares rose about 11% on Friday, outperforming the Nasdaq and the Healthcare sector, amid an AI-healthcare sector rally. The move followed strong peer results, including Doximity’s fiscal Q1 revenue of $156.6 million, and a strategic collaboration with CellCarta adding Tempus to its CDx lab network. TEM traded near $50.95.
4 min readCellCarta (CRO laboratory) said it will add Tempus AI (NASDAQ: TEM) as the second commercial lab partner in its CDx Commercialization Lab Network. Tempus will use Tempus Hub to route oncology companion diagnostic samples to CellCarta and return results to ordering providers. CellCarta also cited Sonic Healthcare USA as the first partner.
2 min readFukushima Ryan (CEO, Data) sold 23,818 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $46.19 ($43.25–$46.94, $1.10M total) across 5 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
2 min readAnalyst estimates cited by FactSet show Tempus AI, Inc. average 12-month price target cut to $62.21 from $63.07. The range is $35 to $100 per share, implying about 42% upside versus the Jul. 31 close. Consensus remains “Buy” with 10 Buys, 7 Holds, and 2 Sells among 19 analysts.
1 min readBTIG cut its Tempus AI (NASDAQ:TEM) price target to $70 from $80 while keeping a Buy rating after the company’s Q2 2026 earnings call. Tempus AI reported 22% YoY revenue growth, raised 2026 revenue guidance to 25% to 26%, and posted $382.5M revenue with an adjusted EPS loss of $0.04. BTIG cited Tempus’s $1.5B Personalis deal with a $46 stock-price termination trigger.
3 min readTipRanks reports that Tempus AI, Inc. Class A (TEM) disclosed risks tied to its proposed acquisition of Personalis. It says integration complexity, higher costs, and possible regulatory scrutiny could reduce the ability to achieve expected synergies. TipRanks also cites an average TEM price target of $65.77, implying 49.92% upside.
2 min readTempus AI (NASDAQ: TEM) agreed to acquire Personalis (PSNL) for $16.25 per share in stock, valuing the deal at about $1.5 billion enterprise value net of Tempus’ existing stake, with closing expected late 2026 or early 2027. Tempus expects integration to expand MRD capabilities. After the July 20 announcement, TEM fell 7.74% intraday. In Q1, revenue rose 36.1% to $348.12M. Needham reiterated Buy at $75; consensus target is $66.75.
5 min readTempus AI (TEM) shares fell after Q2 results. The company reported revenue of $382.5 million, up 22% year over year, and a loss of 4 cents per share, better than the expected 14-cent loss. Revenue beat consensus ($379.7 million), but investors cited slower growth momentum and modest guidance. Stock was down 2.3% to $43.27.
5 min readTempus AI CEO and Chairman Eric P. Lefkofsky sold 250,000 shares of Tempus AI Class A common stock on July 28, 2026, per an SEC Form 4. The sale used a pre-scheduled Rule 10b5-1 plan from March 2026, with a weighted average price of $42.06. Tempus reported Q2 2026 revenue up 20% YoY and agreed to acquire Personalis for $1.5 billion.
6 min readInvesting.com reported Thursday’s US insider trading roundup. Conagra CEO John Brase bought 35,000 shares for $510,632, and Albertsons CEO Susan Morris bought 39,409 shares for $449,937. CoreWeave CEO Michael Intrator sold about $20.5M, Charles Schwab co-chairman Charles Schwab sold about $15.17M, and Snowflake director Benoit Dageville sold $14M, mostly under 10b5-1 plans.
7 min read
